IsoRay (ISR) Reports Q3 Loss of $0.02/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. ELV

Go back to IsoRay (ISR) Reports Q3 Loss of $0.02/Share

IsoRay (ISR) Announces Publication of Positive Cesium-131 Data as Lung Cancer Treatment

May 20, 2015 8:19 AM EDT

IsoRay (NYSE: ISR) announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.

IsoRay CEO Dwight Babcock commented, "We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking... More

Maxim Still Bullish on IsoRay (ISR) Following Q1 Results; More Physicians Adopting Cesium-131

May 18, 2015 2:51 PM EDT

Maxim Group affirms IsoRay (NYSE: ISR) with a Buy rating and $5 price target after the company reported reported Q3 EPS of ($0.02) with revenue of $1.16, versus EPS of ($0.05) and revenue of $1.13 million reported in the same period last year.

Analyst Jason Kolbert noted,... More